Fujisawa Pharmaceutical, Japan’s fifth-largest drugmaker, expects Europe to approve its anti-fungal drug in the first half of 2006.

Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical today announced they have reached an agreement to merge their over-the-counter pharmaceutical businesses and to establish a new joint venture for the purpose.